Jefferies analyst Stephen Barker downgraded PeptiDream to Hold from Buy with a price target of 1,300 yen, down from 1,600 yen. The downgrade reflects eliminating the estimated contribution from a peptide that Bristol Myers Squibb was developing in Phase 1 trials.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PPTDF:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue